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 INTRODUCTION
 Th e management of dysplasia arising in patients with ulcera-
tive colitis (UC) is challenging. Th is is particularly pertinent in 
patients with low-grade dysplasia (LGD)—the most common 
type of dysplasia detected in surveillance programs—as its nat-
ural history of progression to colorectal cancer (CRC) is poorly 
understood. Indeed, the reported risk of CRC associated with 
LGD varies greatly between studies ( 1–9 ). While observed varia-
tion in cancer risk may simply refl ect diff erences in methodology 
and population, there are several other important factors that may 
also have infl uenced outcomes. Th ese include poor interobserver 
agreement in grading dysplasia among histopathologists ( 10,11 ), 
diffi  culty in reliably distinguishing colitis-associated dysplasia 
from sporadic adenomas ( 12 ), and diffi  culty in detecting sub-
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tle dysplastic lesions. Th ese challenges may refl ect the fact that 
LGD is unlikely to be a single entity. Rather, it is likely that there 
is a wide spectrum of malignant potential in the variety of LGD 
lesions that we encounter in clinical practice.
 In 1981, Blackstone  et al. ( 3 ) fi rst introduced the term “dys-
plasia-associated lesion or mass.” Unfortunately, the defi nition of 
dysplasia-associated lesion or mass is not clear and oft en used to 
describe a wide range of lesions, ranging from a small, discrete 
polyp detected in a diseased segment to a large irregular mass. 
However, it is important to diff erentiate these lesions, as their 
malignant potential may vary signifi cantly. For example, it is 
becoming increasingly clear that the risk of CRC is low following 
endoscopic resection of “adenoma-like” lesions arising in patients 
with UC ( 13–16 ).
 Th e challenge is, of course, identifying patients whose LGD 
lesion has a high risk of developing advanced neoplasia from 
those who are at low risk. Although earlier studies demonstrated 
the effi  cacy of endoscopic removal of discrete adenomatous 
lesions without further signifi cant cancer risk, patients who under-
went early colectomy were typically excluded from these analyses 
and their characteristics are poorly understood ( 13–15 ). However, 
this is an important group to consider, as many patients in this 
group represent those who were  clinically judged to be at a high 
risk and hence were off ered colectomy early in their follow-up.
 As one of the ultimate goals of managing LGD is the prompt 
recognition of high-risk lesions that warrant surgical intervention 
from those that can be managed appropriately endoscopically, 
there is a need for a study to assess full spectrum of patients diag-
nosed with LGD to characterize features associated with progres-
sion to more advanced neoplasia.
 To fulfi ll this need, in this study we investigated data collected 
from the UC surveillance program at a large tertiary center in the 
United Kingdom (UK), with the aim of identifying potential risk 
factors that could be used to identify patients with a diagnosis 
of LGD who have a high risk of developing high-grade dysplasia 
(HGD) or CRC.
 METHODS
 Surveillance program
 St Mark’s Hospital is a tertiary referral center in the UK and 
established the UC surveillance program in 1971. Patients with 
endoscopic and histological evidence of UC proximal to the 
splenic fl exure were off ered surveillance colonoscopies every 1 to 
2 years from 8 to 10 years aft er onset of UC symptoms.
 At each colonoscopy, ∼ 8 to 12 segmental random biopsies were 
taken, with multiple targeted biopsies from any suspicious area 
of mucosa. In more recent years (from 2003 onward), there has 
been a gradual increase in number of surveillance procedures per-
formed with chromoendoscopy (CE), where pancolonic dye spray 
is used to highlight abnormal mucosa for targeted biopsies. By 
2011, approximately one in two surveillance colonoscopies were 
performed using this technique.
 Each episode of dysplasia was graded according to the 1983 
Infl ammatory Bowel Disease Dysplasia Morphology Study group 
classifi cation ( 17 ) and was independently reviewed by two expe-
rienced gastrointestinal pathologists at the time of diagnosis in 
accordance with the standard hospital policy.
 Patient identiﬁ cation and inclusion criteria
 Patients with histologically confi rmed extensive UC who had at 
least one episode of LGD detected between 1 January 1993 and 
31 December 2012 were retrospectively identifi ed from St Mark’s 
Hospital’s Infl ammatory Bowel Disease (IBD) database (regis-
tered with National Research Ethics Committee and Northwest 
London Hospitals NHS Trust; reference number, 09/H0717/4).
 Patients who had at least one follow-up colonoscopy or surgi-
cal intervention aft er initial LGD diagnosis were included in the 
study. Patients whose fi rst episode of dysplasia was found inci-
dentally in their colectomy specimen (performed for reasons 
other than dysplasia/CRC, e.g., medically refractory colitis) were 
excluded. Patients who were referred to our institution with dys-
plasia diagnosis already established elsewhere were not consid-
ered in this study.
 Data collection
 Data were collected from the hospital’s IBD database, clinical notes, 
surgical case notes, and endoscopy and histology reports. Detailed 
information on how variables were categorized is described below:
 1.  Macroscopic shape of the dysplastic lesion: patients were cat-
egorized based on the fi rst episode of LGD, according to the 
lesion shape noted at colonoscopy. 
 a.  Polypoid: Paris type 0–I lesions (discrete pedunculated or 
sessile). Examples of polypoid lesions are shown in  Figure 
1a–c . 
 b.  Nonpolypoid: Paris type 0–II (macroscopically  visible fl at, 
slightly elevated or depressed), 0–III (excavated), irregu-
lar, or plaque-like lesions. Th e lesions of any shape with 
evidence of dysplasia in surrounding mucosa were consid-
ered as nonpolypoid. Examples of nonpolypoid lesions are 
shown in  Figure 1d–f . 
 c.  Invisible: absence of documented endoscopic abnormali-
ties. If the visible lesion was detected on subsequent ex-
aminations within 12 months, categorization was based on 
the visible lesion found. 
 d.  When more than one type of lesions were found, the cate-
gorization was based on presence of a lesion with maximal 
carcinogenic potential, in order of nonpolypoid, invisible, 
and polypoid lesions. Th is hierarchy was based on their 
risk of developing HGD or CRC in our preliminary analy-
sis on patients with a single dysplastic lesion only: the haz-
ard ratios (HRs) of patients with nonpolypoid or invisible 
lesions were 16.5 (95% confi dence interval (CI), 5.8–46.5) 
and 6.8 (95% CI, 2.2–21.1), respectively, compared with 
those with polypoid lesions (reference category). 
 2.  Lesion size: each case was categorized based on  presence or 
 absence of the visible dysplastic lesion ≥1 cm in size at colono-
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scopy. When multiple dysplastic lesions were found, the cat-
egorization was based on the largest lesion present. 
 3.  Exposure to chromoendoscopy (CE): the patient was considered 
exposed to CE if he/she had one or more procedures performed 
using CE at the time of or aft er the diagnosis of initial LGD. 
 4.  Multifocal LGD: if dysplasia was found in more than one loca-
tion, the case was considered as multifocal. 
 5.  Metachronous LGD: the patient was considered to have 
metachronous dysplasia if he/she had more than one episode 
of LGD during their surveillance. 
 6.  Other colonoscopic features: data on the presence or absence 
of a documented episode of the following colonoscopic 
appearances were collected: backwash ileitis, colonic stricture, 
postinfl ammatory polyp, scarring, a shortened colon, tubular 
appearance, featureless colon, and presence of severe macro-
scopic infl ammation. Data on the quality of bowel preparation 
and the experience level of endoscopist performing the proce-
dure were also documented (i.e., consultant, trainee, or nurse 
endoscopist). 
 7.  Microscopic infl ammation around the LGD: the data on the 
presence or absence of histological active or chronic infl am-
mation around the site of dysplasia were documented. 
 8.  Family history of CRC: the patient was considered to be posi-
tive if he/she had either fi rst- or second-degree relatives who 
had CRC at any age. 
 9.  Primary sclerosing cholangitis (PSC): the patient was consid-
ered positive only if the diagnosis was confi rmed radiologi-
cally or histologically. 
 10.  Exposure to 5-aminosalicylate or immunosuppressant: 
patients were categorized into three groups depending on the 
duration of exposure to 5-aminosalicylate or immunosup-
pressant since the time of earliest documented use—never, up 
to 10 years, or >10 years. 
 Study end point
 Th e study end point was defi ned as development of HGD or CRC 
during surveillance or at colectomy up to 1 July 2013. If the patient 
had not developed HGD or CRC, they were censored at the earli-
est of: the time of last surveillance colonoscopy, colectomy, or 1 
July 2013.
 Statistical analysis
 Th e data analysis was performed using the SPSS statistical soft -
ware (version 20, IBM, Armonk, NY). All continuous variables are 
reported as medians with interquartile ranges (IQRs). Th e study 
end point was examined using Kaplan–Meier and Cox propor-
tional hazards methods with right-censored data. As 24 potential 
predictors were being tested against two outcomes, a Bonferroni-
adjusted signifi cance level of 0.002 was used to select variables to 
be entered into the multivariate model to minimize the possibility 
of type 1 error.
 RESULTS
 Study population
 A total of 201 patients were diagnosed with LGD between 1 
January 1993 and 31 December 2012. Of these, 15 patients were 
excluded as they withdrew from the surveillance program before 
their next scheduled surveillance for following reasons: death 
(5 patients, all unrelated to CRC), defaulted/patient choice (8 
patients), and transferred to another institution (2 patients). In 
addition, a further 10 patients were excluded as they were sched-
Figure 1. Lesion shape categorization. Discrete sessile (a), pedunculated (b), or sub-pedunculated lesions (c) that were well circumscribed from the 
surrounding mucosa were classiﬁ ed as “polypoid” LGD. Superﬁ cially raised (d and e), visible ﬂ at (f), irregular, or plaque-like lesions were classiﬁ ed as 
“nonpolypoid” LGD.
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uled to have fi rst follow-up colonoscopy aft er the study end date. 
A further four patients were excluded as LGD was incidentally 
found in their surgical specimen from a colectomy performed for 
medically refractory disease. Th us, a total of 172 patients met the 
inclusion criteria.
 Th e demographics of the study population is summarized in 
 Table 1 . LGD was more commonly detected in males (110, 16.0% 
of the male population under surveillance,  n =687) compared 
with females (60, 11.2% of female population under surveillance, 
 n =531; χ 2 ,  P =0.02). Th e median age at initial LGD diagnosis was 
60 years (IQR, 51–67 years) and the median duration of UC at ini-
tial LGD diagnosis was 23 years (IQR, 12–32 years).
 Aft er the initial LGD diagnosis, these 172 patients under-
went a total of 707 additional follow-up surveillance procedures 
(median, 4 procedures per patient; IQR, 2–6), of which 628 were 
colonoscopies (median, 3 colonoscopies per patient; IQR, 1–6). 
Th e median surveillance interval was 12 months (IQR, 7–16 
months). Th e median follow-up duration from initial LGD diag-
nosis to the study end point was 48 months (IQR, 15–87 months), 
with a cumulative patient-year follow-up duration of 850.4 years 
( Table 1 ).
 Patient follow-up
 Of the study population ( n =172), 21 patients (12.2%) underwent 
immediate colectomy without further colonoscopy (i.e., with pre-
surgical diagnosis of LGD only) in a median of 4 months (range, 
2–8 months) aft er initial LGD diagnosis. Histological analysis of 
their surgical specimen revealed CRC in 7 (33.3%), HGD in 3 
(14.3%), LGD in 8 (38.1%), and no neoplasia in 3 patients (14.3%).
 Th e remaining 151 patients initially continued with endoscopic 
surveillance (87.8% of study population). Of these surveyed 
patients, 34 patients (22.5% of patients who remained in sur-
veillance) were subsequently referred to colectomy, 31 of whom 
underwent colectomy at a median of 19 months (IQR, 11–35 
months) aft er initial LGD diagnosis. Indications for colectomy 
were CRC in 4 (all had CRC in specimen), HGD in 11 (of whom 
5 had CRC in specimen), and LGD in 15 patients (of whom 2 
had CRC in specimen), and 1 patient had a colectomy for refrac-
tory colitis (specimen revealed no neoplasia). One patient who 
developed CRC was considered unfi t for surgery and another two 
patients who developed HGD refused surgery and remained in 
surveillance.
 Th e indications for colectomy and the maximal grade of neo-
plasia found in colectomy specimen for all patients who under-
went colectomy during the study period ( n =52) are shown in 
 Table 2 . Overall, when the indication for surgery was HGD, 45.5% 
( n =5/11) of the patients had CRC in their surgical specimen. For 
those who had colectomy for LGD, HGD or CRC was found in the 
colectomy specimens in 38.9% ( n =14/36) of cases, 9 of which were 
CRC (9/36=25.0%;  Table 2 ).
 As of 1 July 2013, 104 patients (60.5% of study population) were 
still under endoscopic follow-up (median, 78.5 months per patient; 
IQR, 46–110 months). Th e surveillance was terminated before 
1 July 2013 in 16 patients (9.3% of study population) because of 
death (7/16 patients, 1 of whom died of CRC without colectomy), 
age (3/16 patients), or patient choice (1/16 patients). Th e remain-
ing 5 patients (2.9% of study population) defaulted on surveillance 
and were lost to follow-up.
 Study end points
 Overall, 33 patients (incidence rate, 38.8 per 1,000 patient-years) 
progressed to more advanced disease during the study period, 
with  n =13 developing HGD (incidence rate, 15.3 per 1,000 
patient-years) and  n =20 developing CRC (incidence rate, 23.5 
per 1,000 patient-years). Only 6 patients (30.0% of patients who 
developed CRC) had a detected HGD lesion before developing 
CRC. Th ere was a wide range in time from LGD to development 
of HGD (median, 13.0 months; IQR, 4.0–37.0 months), or from 
LGD to CRC (median, 10.5 months; IQR, 4.0–36.0 months). 
HGD or CRC was detected either at the surveillance colonoscopy 
( n =16; 48.5% of progressors) or on colectomy ( n =17; 51.5% of 
progressors).
 Characteristics of LGD
 For the majority of patients, the endoscopic shape classifi cation 
of the fi rst LGD lesion was polypoid (116 patients; 67.4% of study 
population), followed by nonpolypoid (39 patients; 22.7%) and 
endoscopically invisible lesions (16 patients; 9.3%). At the time 
of invisible dysplasia detection, bowel preparation was considered 
to be adequate or good in all cases, and the median number of 
random biopsies taken was 11 (IQR, 9–14), and this was not sig-
nifi cantly diff erent from the number of biopsies taken for visible 
lesions (median, 12; IQR, 9–17; Mann–Whitney  U -test,  P =0.4).
 Th irty-six patients had multifocal dysplasia (20.9% of study 
population). Nonpolypoid lesions were notably more likely to 
be multifocal compared with polypoid lesions (19/39=48.7% for 
nonpolypoid vs. 16/116=13.8% for polypoid; Fisher’s exact test, 
 P <0.001). Metachronous LGD lesions were common (79 patients; 
46.0% of study population). Nonpolypoid or invisible lesions were 
more likely to be metachronous compared with polypoid lesions 
(26/39=66.7% for nonpolypoid vs. 41/116=35.3% for polypoid, 
 P <0.001; 12/16=75.0% for invisible vs. 41/116=35.3% for polypoid, 
 P =0.005).
 Table 1 .  Patient demographics ( n =172) 
 Characteristic  Values 
 Male sex (%)  110 (64) 
 Age (median, IQR)  60 Years (51–67) 
 Duration of UC (median, IQR)  23 Years (12–32) 
 Extensive UC (%)  172 (100) 
 Median follow-up duration (IQR)  48 Months (15–87) 
 Median number of follow-up colonoscopy (IQR)  3 Per patient (1–6) 
 Median surveillance interval (IQR)  12 Months (7–16) 
 Median number of biopsies (IQR)  12 (9–17) 
 IQR, interquartile range; UC, ulcerative colitis. 
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least one episode of chromoendoscopy had a slight reduction in 
their risk of HGD or CRC development but this was not signifi -
cant aft er correction for multiple testing (HR, 0.4; 95% CI, 0.2–
0.9;  P =0.02;  Table 4 ).
 Multivariate analysis .  A total of seven variables were entered 
into the multivariate model, the six variables that had a signifi -
cance level  P <0.002 in the univariate analysis and, furthermore, 
 Impact of chromoendoscopy on lesion detection
 A total of 873 colonoscopies (including colonoscopies performed 
before initial LGD detection) were performed for 158 LGD 
patients who were on surveillance between 2003 and 2012, of 
which 285 were chromoendoscopy (32.6%). Th e detection rate 
(i.e., total number of lesions detected/total number of each type 
of colonoscopies performed on study cohort) of the nonpolypoid 
lesion was signifi cantly higher in CE (45/285=15.8%) than white-
light endoscopy (WLE; 46/588=7.8%; χ 2 ,  P <0.001). Th ere was 
no signifi cant diff erence in the detection rate of polypoid lesions 
(17.5% for CE vs. 15.3% for WLE;  P =0.08) and invisible lesions 
(1.8% for CE vs. 1.4% for WLE;  P =0.50) between these two tech-
niques.
 Factors determining development of HGD or CRC
 Univariate analysis .  Th e results of univariate analysis of 
potential demographic, endoscopic, and histological risk factors 
for developing HGD or CRC are shown in  Tables 3–5 , respec-
tively.
 In contrast to patients with polypoid dysplasia, a signifi cant 
risk of developing HGD or CRC was observed among those with 
nonpolypoid dysplasia (HR, 16.5; 95% CI, 6.8–39.8;  P <0.001) or 
endoscopically invisible dysplasia (HR, 6.2; 95% CI, 2.1–18.4; 
 P =0.001;  Table 4 ). Patients with lesions ≥1 cm were more likely 
to develop HGD or CRC (HR, 10.0; 95% CI, 4.3–23.4;  P <0.001) 
compared with those with lesions <1 cm ( Table 4 ). In addition, 
metachronous dysplasia (HR, 3.5; 95% CI, 1.6–7.5;  P =0.001), 
multifocal dysplasia (HR, 3.9; 95% CI, 1.9–7.8;  P <0.001), previ-
ous history of indefi nite dysplasia (HR, 5.0; 95% CI, 2.3–10.9; 
 P <0.001), and a colonic stricture (HR, 7.4; 95% CI, 2.5–22.1; 
 P <0.001) showed a strong correlation to the risk of HGD or CRC 
( Tables 4 and 5 ).
 None of the other variables showed a signifi cant association 
with risk of HGD or CRC, although a nonsignifi cant (at Bonfer-
roni adjusted signifi cance level of 0.002) trend toward the HGD 
or CRC development was observed with coexisting primary 
sclerosing cholangitis (HR, 3.8; 95% CI, 1.3–11.0;  P =0.01), a 
shortened colon (HR, 2.9; 95% CI, 1.2–7.0;  P =0.02), and active 
(HR, 2.1; 95% CI, 1.0–4.4;  P =0.03) or chronic (HR, 3.8; 95% CI, 
1.5–9.9;  P =0.01) microscopic infl ammation in the segment of 
LGD ( Tables 3–5 ). In addition, patients who were exposed to at 
 Table 2 .  Indications for colectomy and the maximal grade of neoplasia found in colectomy specimen 
 Findings in surgical specimen 
 Indication for surgery (no. of patients)  No dysplasia  Indeﬁ nite dysplasia  LGD  HGD  CRC (%) 
 Refractory colitis (1)  1  0  0  0  0 (0) 
 LGD (36)  8  1  13  5  9 (25.0) 
 HGD (11)  0  1  2  3  5 (45.5) 
 CRC (4)  0  0  0  0  4 (100.0) 
 CRC, colorectal cancer; HGD, high-grade dysplasia; LGD, low-grade dysplasia. 
 Table 3 .  Univariate analysis of potential demographic factors 
associated with HGD or CRC 
 Variables  Number (%)  Hazard ratio 
(95% CI) 
 P value 
 Family history of CRC  20 (12)  0.7 (0.2–2.2)  0.5 
 Male sex  110 (64)  1.1 (0.5–2.2)  0.8 
 PSC  10 (6)  3.8 (1.3–11.0)  0.01 
 Duration of UC (years)    
 <10  27 (16)  1  
 10–29  96 (56)  1.0 (0.3–3.1)  0.9 
 >30  49 (28)  1.4 (0.5–4.5)  0.5 
 Age (years)    
 20–39  10 (7)  1  
 40–59  70(40)  2.0 (0.3–15.0)  0.5 
 ≥60  92 (53)  1.6 (0.2–12.0)  0.6 
 5-ASA (years)    
 Never  22 (13)  1  
 Up to 10  72 (42)  0.9 (0.3–2.7)  0.9 
 >10  78 (45)  0.9 (0.3–2.8)  0.9 
 Immunosuppressant (years)    
 Never  109 (63)  1  
 Up to 10  41 (24)  1.2 (0.6–2.6)  0.6 
 >10  22 (13)  0.6 (0.2–2.0)  0.4 
 5-ASA, 5-aminosalicylate; CI, conﬁ dence interval; CRC, colorectal cancer; HGD, 
high-grade dysplasia; PSC, primary sclerosing cholangitis; UC, ulcerative colitis. 
Statistically signiﬁ cant factors ( P <0.002 after correcting for multiple testing) are 
shown in bold.
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exposure to chromoendoscopy ( Table 6 ). Th e rational for the 
inclusion of the latter was to control for the gradual increase in 
the use of chromoendoscopy since 2002 that was likely to be the 
most signifi cant change in the surveillance protocol that has oc-
curred within the study period. Th e mean interval between each 
surveillance colonoscopy had not changed signifi cantly over time 
(1.4 years in 1993–2002 vs. 1.1 years between 2003 and 2012; 
paired  T -test,  P =0.4).
 Aft er multivariate analysis, only nonpolypoid dysplasia 
(HR, 8.6; 95% CI, 3.0–24.8;  P <0.001), endoscopically invis-
ible dysplasia (HR, 4.1; 95% CI, 1.3–13.4;  P =0.02), lesion 
size ≥1 cm (HR, 3.8; 95% CI, 1.5–13.4;  P =0.01), and previous 
history of indefi nite dysplasia (HR, 2.8; 95% CI, 1.2–6.5;  P =0.01) 
remained as signifi cant contributory factors to the HGD or CRC 
outcome ( Table 6 ).
 Factors determining development of CRC only
 Th e analysis was repeated for only CRC cases as the outcome 
( n =20) (i.e., excluding HGD). In the univariate analysis, 
nonpolypoid shape (HR, 18.8; 95% CI, 6.0–59.0;  P <0.001), lesion 
size ≥1 cm (HR, 10.5; 95% CI, 3.5–32.0;  P <0.001), colonic stric-
ture (HR, 16.3, 95% CI, 4.8–54.9;  P <0.001), and previous history 
of indefi nite for dysplasia (HR, 5.8; 95% CI, 2.2–15.4;  P <0.001) 
showed a signifi cant association with development of CRC. None 
of the other variables were signifi cant.
 Table 4 .  Univariate analysis of potential endoscopic factors 
associated with HGD or CRC 
 Variables  Number (%) a  Hazard ratio 
(95% CI) 
 P value 
 Lesion shape    
 Polypoid  116 (67)  1  
  Nonpolypoid  39 ( 23)  16.5 ( 6.8–39.8)  <0.001 
  Invisible  16 ( 9)  6.2 ( 2.1–18.4)  0.001 
 Large lesion (≥1 cm)  60 ( 35)  10.0 ( 4.3–23.4)  <0.001 
 Chromoendoscopy use  112 (65)  0.4 (0.2 – 0.9)  0.02 
 Endoscopist    
 Consultant  119 (69)  1  
 Trainee or nurse  46 (27)  1.3 (0.6–2.9)  0.5 
 Bowel preparation    
 Good/adequate  156 (91)  1  
 Poor  9 (5)  1.9 (0.6–3.9)  0.3 
 Backwash ileitis  18 (10)  2.2 (0.6–6.3)  0.3 
 Featureless colon  27 (16)  1.8 (0.8–4.1)  0.1 
 Pseudopolyps  108 (63)  0.8 (0.4–1.5)  0.4 
 Shortened colon  16 (9)  2.9 (1.2–7.0)  0.02 
 Scarring  114 (66)  0.8 (0.4–1.7)  0.6 
 Stricture  6 ( 3)  7.4 ( 2.5 – 22.1)  <0.001 
 Tubular colon  60 (35)  1.3 (0.6–2.5)  0.5 
 CI, conﬁ dence interval; CRC, colorectal cancer; HGD, high-grade dysplasia. 
 a Variable categorization was not possible because of lack of documentation in fol-
lowing cases: lesion shape (1 case; 1% of study population), lesion size (2; 1%), 
experience of endoscopist (7; 4%), and quality of bowel preparation (7; 4%). 
 Statistically signiﬁ cant factors ( P <0.002 after correcting for multiple testing) are 
shown in bold. 
 Table 5 .  Univariate analysis of potential histological factors 
associated with HGD or CRC 
 Variables  Number (%) a  Hazard ratio 
(95% CI) 
 P value 
 Metachronous  79 (46)  3.5 (1.6–7.5)  0.001 
 Previous indeﬁ nite 
dysplasia 
 17 (10)  5.0 (2.3–10.9)  <0.001 
 Multifocal  36 (21)  3.9 (1.9–7.8)  <0.001 
 Location b    
 Proximal  74 (43)  1  
 Distal  74(43)  2.0 (1.0–4.4)  0.07 
 Both  13 (8)  —  — 
 Inﬂ ammation a    
 Normal/quiescent  100 (58)  1  
 Chronic  15 (8)  3.8 (1.5–9.9)  0.01 
 Active  56 (33)  2.1 (1.0–4.4)  0.03 
 CI, conﬁ dence interval; CRC, colorectal cancer; HGD, high-grade dysplasia. 
 a Refers to microscopic inﬂ ammation in the segment of dysplasia. In one case 
this was unknown because of lack of documentation (1% of study population). 
 b Refers to location in relation to splenic ﬂ exure. The location of LGD was 
unknown in 11 invisible dysplasia cases (6%). 
 Statistically signiﬁ cant factors ( P <0.002 after correcting for multiple testing) are 
shown in bold. 
 Table 6 .  Final multivariate model showing signiﬁ cant factors 
independently associated with HGD or CRC development 
 Variables  Hazard ratio (95% CI)  P value 
 LGD lesion shape   
 Polypoid  1  
  Nonpolypoid  8.6 (3.0–24.8)  <0.001 
  Invisible  4.1 (1.3–13.4)  0.02 
 Large lesion (≥1 cm)  3.8 (1.5–13.4)  0.01 
 Stricture  1.6 (0.5–5.4)  0.4 
 Metachronous  1.3 (0.5–3.4)  0.6 
 Previous indeﬁ nite dysplasia  2.8 (1.2–6.5)  0.01 
 Multifocal  1.8 (0.6–4.6)  0.3 
 Chromoendoscopy use  0.5 (0.3–1.0)  0.06 
 CI, conﬁ dence interval; CRC, colorectal cancer; HGD, high-grade dysplasia; 
LGD, low-grade dysplasia. 
 Statistically signiﬁ cant factors ( P <0.05) are shown in bold. 
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HGD or CRC at 1 and 5 years was 29.8% and 47.3% (HR, 12.6%; 
s.e., 2.4%), respectively (in contrast with a lesion <1 cm in size, 
for which these were 0.4% and 5.8% (HR, 1.2%; s.e., 0.5%); 
 Figure 2c ). If the fi rst episode of LGD was preceded by indefi -
nite dysplasia, the cumulative incidence of HGD or CRC at 1 and 
5 years was 24.3% and 55.7% (HR, 16.0%; s.e., 5.1%), respective-
ly. If the LGD was the fi rst dysplasia, this was 9.4% and 15.8% 
(HR, 3.7%; s.e., 0.8%;  Figure 2d ), respectively.
 Based on total number of risk factors .  Th ere was a signifi cant 
positive correlation between the number of risk factors present 
and the cumulative risk of developing HGD or CRC (log-rank 
test,  P <0.001;  Figure 3 ). Th e cumulative incidence of HGD or 
CRC at 1 and 5 years aft er initial LGD was 0 and 1.8% for no risk 
factor (HR, 0.3%; s.e., 0.2%), 9.6 and 17.7% for one risk factor 
(HR, 4.9%; s.e., 1.8%), and 29.0 and 53.4% for two risk factors 
(HR, 13.6%; s.e., 3.3%). For those with three risk factors, cumula-
tive risk of HGD or CRC development was 61.6% and 80.7% at 1 
and 2 years, respectively ( Table 7 ).
 In patients who remained in surveillance .  We performed same 
analysis excluding patients who underwent immediate colectomy 
( n =21). Th e cumulative incidence of HGD or CRC development 
based on lesion shape, size, preceding dysplasia, and the total 
number of these risk factors present in the fi rst 10 years from 
 Aft er multivariate analysis, only nonpolypoid shape (HR, 
10.1; 95% CI, 2.4–42.8;  P =0.002) and lesion size ≥1 cm (HR, 3.6; 
95% CI, 1.04–12.6;  P =0.04) remained as signifi cant contributory 
factor to the CRC outcome. Th e previous history of indefi nite 
for dysplasia (HR, 2.9; 95% CI, 0.99–8.6;  P =0.053) and colonic 
stricture (HR, 3.7; 95% CI, 0.99–13.9;  P =0.052) showed 
strong trend toward CRC outcome, but this was not statistically 
signifi cant.
 Rate of progression to HGD or CRC
 Overall .  Overall cumulative incidence of HGD or CRC develop-
ment at 1 and 5 years aft er initial LGD diagnosis was 10.9% and 
19.5%, respectively (mean annual hazard rate in fi rst 5 years (HR), 
4.7%, s.e., 0.9%;  Figure 2a ).
 Based on individual risk factors .  Th e cumulative incidence 
of HGD or CRC development based on lesion shape, size, and 
preceding dysplasia in the fi rst 10 years from the date of initial 
LGD diagnosis is shown in  Table 7 . Th e cumulative incidence of 
HGD or CRC at 1 and 5 years aft er initial LGD was 3.5% and 6.0% 
for polypoid (HR, 1.3%; s.e., 0.6%), 6.7% and 21.9% for invisible 
(HR, 4.6%; s.e., 2.6%), and 36.6% and 65.2% for nonpolypoid 
LGD (HR, 18.2%; s.e., 3.6%), respectively ( Figure 2b ). When a 
large lesion (≥1 cm in size) was found, the cumulative incidence of 
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 Figure 2 .  Kaplan–Meier plots showing cumulative risk of developing high-grade dysplasia (HGD) or colorectal cancer (CRC). ( a ) Overall cumulative risk. 
( b ) Cumulative risk by low-grade dysplasia (LGD) lesion shape. ( c ) Cumulative risk by LGD lesion size. ( d ) Cumulative risk depending on the presence or 
absence of preceding indeﬁ nite dysplasia. 
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the date of initial LGD diagnosis is shown in  Supplementary 
Table S1 and  Supplementary Figure S1–S2 online.
 DISCUSSION
 In this study, we performed a detailed analysis of HGD and 
CRC risk in a large number of UC patients diagnosed with 
LGD, taking their demographic, endoscopic, and histological 
characteristics into account. We have shown that UC patients with 
LGD that is non-polypoid, invisible, ≥1 cm in size, or preceded 
by indefi nite dysplasia are at higher risk of developing HGD or 
CRC. In addition, we have described several other features that 
had a signifi cant association with development of HGD or CRC 
in univariate analysis that may be useful in identifying high-risk 
patients.
 Non-polypoid dysplastic lesions
 In agreement with previous studies, our data shows that poly-
poid LGD lesions have a low risk of CRC ( 13,14,16,18 ). Polypoid 
lesions were the most common form of LGD found in our cohort 
and were removed endoscopically in the vast majority of 
cases (108/116 or 93.1%) suggesting that the majority of LGD 
lesions may be adequately managed without colectomy. It was 
previously shown that the risk of CRC was similar between 
adenoma-like lesions arising in diseased segment and spo-
radic adenoma occurring in disease-free segment ( 14,15 ), and 
furthermore studies have suggested that these lesions have 
genetic similarities ( 12,19 ). Th us, it is possible that adenoma-like 
lesions may simply represent sporadic adenomas that occur in 
patients with UC.
 Patients with non-polypoid lesions, however, had a signifi cantly 
higher cancer risk. Many of these lesions were not amenable for 
endoscopic resection (24 out of 39 or 61.5% of non-polypoid 
lesions), and were more likely to be multifocal compared with 
polypoid lesions. In our cohort, 13 out of 39 patients (33.3%) 
who initially had a LGD lesion that was considered nonpolypoid 
in shape later developed CRC. In addition, 6 of these 
 Table 7 .  The cumulative incidence of HGD or CRC development based on lesion shape, size, preceding indeﬁ nite dysplasia, and total 
number of these risk factors present in the ﬁ rst 10 years from the date of initial LGD diagnosis 
 Cumulative incidence of HGD or CRC (%) 
 Years  1  2  3  4  5  6  7  8  9  10 
 Overall  10.9  13.6  16.7  17.5  19.5  19.5  22.3  24.3  24.3  27.1 
 By lesion shape 
 Polypoid  3.5  3.5  4.6  4.6  6.0  6.0  8.0  8.0  8.0  8.0 
 Invisible  6.7  14.1  21.9  21.9  21.9  21.9  31.7  42.2  42.2  56.7 
 Nonpolypoid  36.6  46.7  54.2  58.8  65.2  65.2  65.2  65.2  65.2  65.2 
 By lesion size 
 <1 cm  0.4  2.0  3.1  4.3  5.8  5.8  7.8  10.7  10.7  10.7 
 ≥1 cm  29.8  36.2  43.7  43.7  47.3  47.3  47.3  47.3  47.3  59.0 
 Preceding indeﬁ nite dysplasia 
 No  9.4  10.9  12.6  13.6  15.8  15.8  17.3  19.3  19.3  22.3 
 Yes  24.3  38.1  55.7  55.7  55.7  55.7  85.3  —  —  — 
 Total number of risk factors (shape, size, or preceding indeﬁ nite dysplasia ) 
 None  0.0  0.0  0.0  0.0  1.8  1.8  1.8  1.8  1.8  1.8 
 1  9.6  9.6  13.1  17.7  17.7  17.7  17.7  41.1  41.1  41.1 
 2  29.0  40.5  48.8  48.8  53.4  53.4  58.9  58.9  58.9  70.6 
 3  61.6  80.7  —  —  —  —  —  —  —  — 
 CRC, colorectal cancer; HGD, high-grade dysplasia; LGD, low-grade dysplasia. 
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 Figure 3 .  Kaplan–Meier plot showing the cumulative risk of high-grade 
dysplasia (HGD) or colorectal cancer (CRC) development depending on 
total number of risk factors present (i.e., any combinations of nonpolypoid 
or invisible low-grade dysplasia (LGD), LGD sized ≥1 cm, and/or preceding 
indeﬁ nite dysplasia). 
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1,000 patient-years between 1993 and 2002), although this was 
not statistically signifi cant (Fisher’s exact,  P =0.07). In contrast, the 
incidence rate of non-polypoid lesions increased by two-fold in 
the recent decade (36.2 per 1,000 patient-years between 2003 and 
2012) compared with the previous decade (18.8 per 1,000 patient-
years between 1993 and 2002).
 Th ese fi ndings may suggest that invisible dysplasia is becoming 
a rare entity and is instead being increasingly detected as non-
polypoid dysplasia, as improving endoscopic techniques and tech-
nologies allow detection of more subtle lesions. Th is may explain 
why patients with invisible dysplasia had a relatively high risk of 
progression to HGD or CRC. Nevertheless, it is important to con-
fi rm the nature of these invisible lesions in a dedicated study, as it 
is still possible that these are truly invisible lesions that are diffi  cult 
to detect even with advanced techniques.
 Th us, when an invisible dysplasia is detected, our current policy 
is to refer patients to an experienced endoscopist to have a repeat 
procedure performed with an advanced technique. Typically, HD 
CE is performed in an attempt to identify the lesion that was pos-
sibly missed in previous colonoscopy. In addition, segmental and 
targeted biopsies are taken as appropriate to ensure that any truly 
invisible lesions are not missed.
 Preceding dysplasia
 Th e previous history of indefi nite for dysplasia showed a signifi -
cant association with development of HGD or CRC. It is recog-
nized that distinction between indefi nite for dysplasia and LGD 
is challenging ( 11 ) and it was previously shown that indefi nite 
dysplasia is frequently regraded to LGD aft er a dedicated review 
( 28 ). Th us, one possible explanation is that these indefi nite dys-
plasia may actually have been LGD. Furthermore, patients with 
metachronous LGD had high risk of developing HGD or CRC in 
a univariate analysis, suggesting that persistent dysplasia regard-
less of grade may increase the risk of progression. Patients with 
dysplasia with previous a history of any grade of dysplasia should 
therefore be closely monitored, and option for colectomy should 
be discussed with the patient if metachronous dysplasia develops 
persistently despite endoscopic resection.
 Other risk factors
 Several studies have documented a high rate of underlying 
CRC among patients with colonic stricture ( 29,30 ). In our 
study, four out of six patients with a colonic stricture had 
developed CRC. In particular, all three patients whose dys-
plasia was found within a stricture had advanced CRC. In the 
remaining patient, CRC (Dukes’ B) was found proximal to the 
stricture, indicating that diffi  culty in access to the proximal 
colon may have been a contributing factor. Although the patient 
number is small in our cohort, the high proportion of patients 
who developed CRC indicates that fi nding a colonic stricture in 
patients with history of dysplasia should raise clinical suspicion 
for CRC.
 Although multifocal dysplasia is generally perceived to be 
a high-risk feature, the evidence demonstrating this is scant 
( 28,31 ). In our study, multifocal dysplasia showed a signifi cant 
patients (6/13=46.2% of patients who developed CRC) had 
synchronous cancers in the surgical specimen. Th ese lesions 
are an ominous fi nding and thus may require more aggressive 
management.
 Of note, our results suggest that the CE was more eff ective at 
detecting non-polypoid lesions than WLE but the diff erence was 
minimal for polypoid lesions, and this is broadly in agreement 
with previous randomized controlled trial ( 20 ) and a recent meta-
analysis ( 21 ). Given the signifi cant risk of progression associated 
with nonpolypoid lesions, our data advocate the use of CE for early 
detection of these higher-risk lesions. As high-defi nition (HD) 
colonoscopy (i.e., HD colonoscope with HD-monitor) was only 
available since 2011 in our center, its effi  cacy could not be reliably 
assessed in our study. Th e value of HD WLE in detecting subtle 
dysplastic lesions compared with CE thus requires further dedi-
cated study.
 Large dysplastic lesions
 It is well established that the malignant potential of a sporadic 
adenoma increases with size ( 22–24 ). However, the correlation of 
dysplastic lesion size and malignant potential in IBD is not well 
established. Our data suggest that lesions that are ≥1 cm have an 
approximately four-fold greater risk of progression compared 
with smaller lesions. Th is fi nding is in agreement with the data 
from IBD-free population where lesions >1 cm (or “advanced 
adenomas”) were associated with ∼ 3.6-fold increased risk of CRC 
compared with the general population ( 24 ). It was recently shown 
that the incomplete resection rate is higher for larger adenomas 
(10–20 mm) or non-conventional adenomas ( 25 ) and it is likely 
that a large non-polypoid dysplastic lesions in colitis are simi-
larly more diffi  cult to resect completely. Th us, it is important that 
advanced techniques are used when such lesion is being managed 
non-operatively, and if the complete resection cannot be achieved, 
colectomy may be advisable.
 Although these results should provide a broad guidance in mak-
ing management decisions, our data should be confi rmed by pro-
spective trials, as our retrospective study design limits adequate 
assessment for possible interobserver variability that may exist 
in classifying the lesion shape and size that was recently demon-
strated to be only moderate ( 26 ).
 Invisible dysplasia
 Although most dysplastic lesions were endoscopically visible in 
our study, the presence of invisible dysplasia detected histologi-
cally within a random biopsy was a signifi cant risk factor for HGD 
or CRC development in our multivariate analysis. Our results are 
in agreement with previous retrospective study from the US ter-
tiary center ( 1 ) and a meta-analysis ( 27 ).
 However, it should be noted that these studies were performed 
before the introduction of newer techniques, in particular, CE. It 
is diffi  cult to know whether these “invisible” lesions were truly 
endoscopically invisible dysplasias or simply “missed” lesions.
 In our data set, the incidence rate of invisible dysplasia in the 
recent decade was lower (7.4 per 1,000 patient-years between 
2003 and 2012) compared with the previous decade (18.8 per 
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association toward development of HGD or CRC in a univariate 
setting only, highlighting the importance of considering other 
independent risk factors in conjunction. For example, none 
of the patients with multifocal polypoid dysplasia ( n =12) had 
developed HGD or CRC during a median of 63 months (IQR, 
63–111 months).
 Number of risk factors present and timing of colectomy
 We observed a clear association between the numbers of risk 
factors present (i.e., lesion shape, size, and preceding indefi nite 
dysplasia) and the risk of HGD or CRC development. Of note, 
patients with only one of these risk factors had 17.7% risk of pro-
gression at 5 years aft er initial LGD diagnosis.
 Relatively low rate of progression observed in this group is per-
haps not surprising, as it represent LGD cases that could be poten-
tially removed endoscopically. For example, 18 patients (without 
preceding dysplasia) had their large polypoid LGD removed endo-
scopically (median size, 15 mm; IQR, 10–25 mm). During median 
follow-up of 33 months (IQR, 15–49 months), 2 of these patients 
developed CRC (both Dukes’ A) in 6 and 24 months aft er resection 
and 1 patient developed HGD in 6 months (incidence rate, 45.5 
per 1,000 patient-years).
 Similarly, of 8 patients who underwent endoscopic resec-
tion for small (<1 cm) nonpolypoid lesions, 1 patient developed 
CRC (Dukes’ A) in median follow-up of 44 months (IQR, 26–66 
months; incidence rate, 26.8 per 1,000 patient-years). Th us, these 
data suggest that colectomy may not be always necessary for this 
group of patients, provided that the lesion can be resected in full 
with no evidence of dysplasia elsewhere in the colon. However, 
given the small number of cases, these data should be interpreted 
with caution.
 In contrast, when patients had 2 risk factors, their risk of 
developing HGD or CRC exceeded 50% at 5 years following 
their initial LGD diagnosis. Furthermore, when all 3 risk factors 
were present, >80% of patients developed HGD or CRC within 2 
years. Th us, these patients should be considered for early surgical 
intervention and counseling should be off ered at the earliest 
opportunity.
 Of note, only 30% (6/20) of CRCs were preceded by HGD in 
our cohort, indicating that a majority of CRCs were detected 
during colectomy performed for LGD (9/20; 45%) or at surveil-
lance colonoscopy with last known worst dysplasia being LGD 
(5/20; 25%). Th us, our data suggest that the time when LGD is 
detected is likely to be the most appropriate time for assessing the 
risk associated with the lesion and off er surgical intervention for 
appropriate patients.
 Limitations
 Our study has limitations. First, it could be considered that our 
inclusion of patients who underwent early colectomy may have 
limited the accurate assessment of the natural history of LGD. 
Th is issue is particularly true for those patients with small poly-
poid LGD lesions who undergo early colectomy, as risk of HGD or 
CRC associated with such lesions may be underestimated. How-
ever, such cases are very rare in our experience: in our cohort, 
only 1 patient out of 31 patients underwent colectomy within 12 
months for LGD without having any of the aforementioned high-
risk features (and no dysplasia or CRC was detected in the colec-
tomy specimen). Moreover, excluding early colectomy patients 
entirely may potentially lead to underestimation of the risk asso-
ciated with lesions with the aforementioned high-risk features as 
they oft en underwent colectomy within 12 months from initial 
LGD diagnosis ( n =30/31, 14 of whom had HGD or CRC in the 
specimen).
 Second, this study was conducted on a cohort from a tertiary 
referral center that includes a higher proportion of patients with 
more severe or complex disease. Th is has a potential impact on 
generalizability of our results, as the progression of LGDs in non-
tertiary centers may be diff erent. For example, it is possible that 
dysplastic lesions studied in our work may represent those devel-
oped on background of more severe infl ammatory drive, hence 
leading to more rapid progression. Furthermore, the rate of dys-
plasia detection and endoscopic removal may also vary signifi -
cantly between centers.
 CONCLUSION
 In summary, we have revealed three important independent risk 
factors for HGD or CRC development in patients with LGD: lesion 
shape (non-polypoid or macroscopically invisible dysplasia), size 
of the lesion ≥1 cm, and history of previous indefi nite for dysplasia. 
Patients with a LGD lesion who exhibit these risk factors have a 
high risk of developing HGD or CRC. Th erefore, early surgical 
intervention should be considered in close discussion with the 
patient, particularly when more than one of these risk factors is 
present. Conversely, patients with small (<1 cm) polypoid lesion 
may be appropriately managed with endoscopic resection with 
close monitoring. Patients with multifocal dysplasia, previous 
history of  any grade of dysplasia, and colonic stricture should be 
regarded as a considerable risk and intensive surveillance should 
be considered.
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 Study Highlights
 WHAT IS CURRENT KNOWLEDGE 
 ✓  Patients with ulcerative colitis (UC) who are diagnosed with 
low-grade dysplasia (LGD) have a signiﬁ cant risk of developing 
colorectal cancer (CRC). However, management of these 
patients is challenging because of marked variability in 
their rate of progression to more advanced neoplasia. 
 ✓  There are little data on endoscopic and histological char-
acteristics of LGD that are associated with a high risk of 
development of high-grade dysplasia (HGD) or CRC. 
 WHAT IS NEW HERE 
 ✓  Patients with a LGD lesion that is non-polypoid in shape, 
endoscopically invisible, sized ≥1 cm or preceded by 
“indeﬁ nite for dysplasia” diagnosis have a high risk of 
developing HGD or CRC. 
 ✓  Chromoendoscopy was more effective at detecting non-
polypoid dysplasias than white-light endoscopy. 
 ✓  If one or more of these risk factors are present, patients 
should be carefully counseled about their management 
options including colectomy. 
 ✓  Conversely, patients with a small polypoid lesion and no 
other risk factors may be appropriately managed with close 
surveillance. 
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